Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818264 | 0.82 | MGLL (0.52) | PTGDR2MGLLFAAH | |
| SCHEMBL14645770 | 0.79 | MGLL (0.56) | CHRM4PTGDR2MGLL | |
| SCHEMBL20139939 | 0.77 | GRM1 (0.67) | CHRM4GRM1 | |
| SCHEMBL27034618 | 0.77 | DPP4 (0.53) | CHRM4PTGDR2CHRM1 | |
| SCHEMBL19381835 | 0.75 | ACHE (0.51) | CHRM4TACR1COMTBRD4CHRM1 | |
| SCHEMBL28024574 | 0.75 | COMT (0.53) | TACR1COMTCHRM1 | |
| SCHEMBL20804350 | 0.75 | COMT (0.53) | TACR1COMTCHRM1 | |
| SCHEMBL3215246 | 0.75 | PTGDR2 (0.41) | CHRM4PTGDR2MGLLFAAH | |
| SCHEMBL28352108 | 0.74 | KCNH2 (0.44) | CHRM4PTGDR2MGLLFAAH | |
| SCHEMBL28352107 | 0.74 | KCNH2 (0.44) | CHRM4PTGDR2MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | CHRM4 4454/4885TACR1 3799/4885COMT 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.